Coming October 2: SITC releases abstract titles with each presenting author’s institution (nearly 1,300 last year). We’ll add them to this guide once they’re out.

Merck & Co. at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

Merck & Co. brings 1 presentation to SITC 2026 in Phoenix, and exhibits at Booth 1228. Its presence centres on checkpoint inhibitors, bispecifics and other new agents, along with clinical trials and patient care. Merck & Co., called MSD beyond the US and Canada, brings a wide oncology research and clinical development effort.

OrganizationSITC 2026 Attendance
Merck & Co.
Rahway, NJ
Large pharma
Global pharmaceutical company, known as MSD outside the US and Canada, running a broad oncology research and clinical development program.
Booth
Exhibiting at Booth 1228
Fri, Nov 610:00am–2:00pm · 5:00pm–7:00pmSat, Nov 710:00am–2:00pm · 6:00pm–8:10pm
Session
Wed Nov 4
3:10pm–3:55pm
Session
Thu Nov 5
6:55pm–7:15pm
Panel
Session
Fri Nov 6
3:55pm–5:30pm
Biotech Session: The Next Generation of Off-the-Shelf IO
Cell therapy
  1. 3:55pm–4:10pmNext-gen T Cell Engagers
  2. 4:10pm–4:25pmIn vivo Cell Therapy Platforms for CancerEli Lilly and Company
  3. 4:25pm–4:40pmAllogeneic Cell TherapiesAllogene Therapeutics
  4. 4:40pm–5:00pm2 abstract presentations — titles not yet released
  5. 5:00pm–5:30pmIn Vivo - Ex Vivo DebateKite Pharma, Massachusetts Institute of Technology, Roswell Park Comprehensive Cancer Center, Azalea Therapeutics

Explore the full SITC 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Phoenix. Leave your work email and we’ll be in touch.

Privacy

Download the full SITC 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Merck & Co.

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the Society for Immunotherapy of Cancer (SITC). Submit a correction